leadf
logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics celebrating 20 years of growth and innovation

Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman discuss with Proactive London's Andrew Scott the group's results for the six months to December 2018.

The company saw turnover rise 10.6% to £46.7mln in the period, up from £42.2mln a year earlier.

2019 is Allergy's 20th anniversary since they spun out of GlaxoSmithKline.

Quick facts: Allergy Therapeutics PLC

Price: 15.5 GBX

AIM:AGY
Market: AIM
Market Cap: £98.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: Weaker pound steers FTSE higher, while Tesla drives investors...

The FTSE is higher this Wednesday. One of the main talking points today - is Tesla (NASDAQ: TSLA) after much anticipation leading up to CEO Elon Musk’s announcement - it failed to impress - slashing $50 billion from Tesla's market value after a promise to cut electric vehicle costs so...

2 days ago

2 min read